Business
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
- Planned submission for U.S. Accelerated Approval of z-rostudirsen on track for Q2 2026; potential launch in Q1 2027 - - Positive topline results reported from Phase 1/2 DELIVER trial of z-rostudirsen in exon 51 skip amenable Duchenne muscular dystrophy (DMD); additional long-term data to be presented at MDA - - Completion of enrollment in registrational expansion cohort of Phase 1/2 ACHIEVE trial of z-basivarsen in myotonic dystrophy type 1 (DM1) expected in Q2 2026; Phase 3 trial design to be
About this update from Dyne Therapeutics, Inc.
[{"type":"image","alt":"Dyne Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Dyne Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":91,"url":"https://media.zenfs.com/en/globenewswire.com/e818a029eb02ef26c3902e74a3e0ec39"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nro7S6xW_IUN_DBx15qegw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e818a029eb02ef26c3902e74a3e0ec39","width":300,"height":91}},"lazy":false},{"type":"text","content":"- Planned submission for U.S. Accelerated Approval of z-rostudirsen on track for Q2 2026; potential launch in Q1 2027 -","length":119,"tagName":"p"},{"type":"text","content":"- Positive topline results reported from Phase 1/2 DELIVER trial of z-rostudirsen in exon 51 skip amenable Duchenne muscular dystrophy (DMD); additional long-term data to be presented at MDA -","length":192,"tagName":"p"},{"type":"text","content":"- Completion of enrollment in registrational expansion cohort of Phase 1/2 ACHIEVE trial of z-basivarsen in myotonic dystrophy type 1 (DM1) expected in Q2 2026; Phase 3 trial design to be presented at MDA -","length":206,"tagName":"p"},{"type":"text","content":"- Advancing four development candidates for the potential treatment of DMD amenable to skipping of exons 53, 45, 44, and 55 -","length":125,"tagName":"p"},{"type":"text","content":"- Year-end cash of $1.1 billion; reaffirming expected cash runway into Q1 2028 -","length":80,"tagName":"p"},{"type":"text","content":"WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today reported financial results for the fourth quarter and full year 2025 and recent business highlights.","length":332,"tagName":"p"},{"type":"text","content":"“Dyne is entering a critical period of transformation as we advance programs from our clinically validated FORCE platform toward commercialization, with our first potential launch in DMD in less than 12 months, if Priority Review is granted and approval is received. The positive topline results we reported in December for z-rostudirsen further demonstrate the potential of the FORCE platform to safely and effectively deliver drug payloads bro...